Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500

Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500

AVB‐S6‐500 neutralized growth arrest‐specific 6 (GAS6) protein and effectively inhibited AXL signaling in preclinical cancer models. A target‐mediated drug disposition (TMDD) pharmacokinetic/pharmacodynamic (PK/PD) model was used to select first‐in‐human (FIH) doses for AVB‐S6‐500 based on predicted...

Full description

Bibliographic Details
Main Authors: Laura Bonifacio, Michael Dodds, David Prohaska, Aaron Moss, Amato Giaccia, Ray Tabibiazar, Gail McIntyre
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.12706

Internet

https://doi.org/10.1111/cts.12706

Similar Items